

Paul A Foster

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1048159/publications.pdf>

Version: 2024-02-01

56
papers

2,177
citations

218677

26
h-index

233421

45
g-index

56
all docs

56
docs citations

56
times ranked

2716
citing authors

#	ARTICLE	IF	CITATIONS
1	The Regulation of Steroid Action by Sulfation and Desulfation. <i>Endocrine Reviews</i> , 2015, 36, 526-563.	20.1	310
2	Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 1386-1391.	7.1	195
3	Natriuretic Peptide Receptor-C Regulates Coronary Blood Flow and Prevents Myocardial Ischemia/Reperfusion Injury. <i>Circulation</i> , 2004, 110, 1231-1235.	1.6	134
4	Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers. <i>Journal of Endocrinology</i> , 2012, 212, 99-110.	2.6	118
5	17 β -hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer. <i>International Journal of Cancer</i> , 2008, 122, 1931-1940.	5.1	99
6	Quinazolinone-Based Anticancer Agents: Synthesis, Antiproliferative SAR, Antitubulin Activity, and Tubulin Co-crystal Structure. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 1031-1044.	6.4	91
7	C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 14452-14457.	7.1	87
8	In vivo Efficacy of STX213, A Second-Generation Steroid Sulfatase Inhibitor, for Hormone-Dependent Breast Cancer Therapy. <i>Clinical Cancer Research</i> , 2006, 12, 5543-5549.	7.0	62
9	Protein disulphide isomerase inhibition as a potential cancer therapeutic strategy. <i>Cancer Medicine</i> , 2021, 10, 2812-2825.	2.8	51
10	Structure-Activity Relationships of C-17 Cyano-Substituted Estratrienes as Anticancer Agents. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 1295-1308.	6.4	50
11	Oestrogen and colorectal cancer: mechanisms and controversies. <i>International Journal of Colorectal Disease</i> , 2013, 28, 737-749.	2.2	49
12	NNT is a key regulator of adrenal redox homeostasis and steroidogenesis in male mice. <i>Journal of Endocrinology</i> , 2018, 236, 13-28.	2.6	46
13	STX140 Is Efficacious <i>In vitro</i> and <i>In vivo</i> in Taxane-Resistant Breast Carcinoma Cells. <i>Clinical Cancer Research</i> , 2008, 14, 597-606.	7.0	42
14	In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol. <i>British Journal of Cancer</i> , 2007, 96, 1368-1376.	6.4	39
15	Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, <i>in vitro</i> and <i>in vivo</i> activities, molecular modeling, and protein crystallography. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2435-2444.	4.1	39
16	The Use of Steroid Sulfatase Inhibitors as a Novel Therapeutic Strategy Against Hormone-Dependent Endometrial Cancer. <i>Endocrinology</i> , 2008, 149, 4035-4042.	2.8	39
17	2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer. <i>British Journal of Cancer</i> , 2008, 99, 1842-1848.	6.4	37
18	A New Therapeutic Strategy against Hormone-Dependent Breast Cancer: The Preclinical Development of a Dual Aromatase and Sulfatase Inhibitor. <i>Clinical Cancer Research</i> , 2008, 14, 6469-6477.	7.0	37

#	ARTICLE	IF	CITATIONS
19	The Development of Steroid Sulfatase Inhibitors for Hormone-Dependent Cancer Therapy. <i>Annals of the New York Academy of Sciences</i> , 2009, 1155, 80-87.	3.8	37
20	Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 111, 129-138.	2.5	34
21	SULFATION PATHWAYS: Insights into steroid sulfation and desulfation pathways. <i>Journal of Molecular Endocrinology</i> , 2018, 61, T271-T283.	2.5	34
22	Recent Developments of Steroid Sulfatase Inhibitors as Anti-Cancer Agents. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2008, 8, 732-738.	1.7	33
23	Estrogen Activation by Steroid Sulfatase Increases Colorectal Cancer Proliferation via GPER. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4435-4447.	3.6	31
24	Steroid Sulphatase and Its Inhibitors: Past, Present and Future. <i>Molecules</i> , 2021, 26, 2852.	3.8	30
25	A comparative study of the ability of calcitonin gene-related peptide and adrenomedullin13-52 to modulate microvascular but not thermal hyperalgesia responses. <i>British Journal of Pharmacology</i> , 2000, 130, 1589-1596.	5.4	29
26	2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique. <i>Breast Cancer Research and Treatment</i> , 2008, 111, 251-260.	2.5	29
27	¹ H NMR-MS-based heterocovariance as a drug discovery tool for fishing bioactive compounds out of a complex mixture of structural analogues. <i>Scientific Reports</i> , 2019, 9, 11113.	3.3	28
28	Design, synthesis, and biological evaluation of new arylamide derivatives possessing sulfonate or sulfamate moieties as steroid sulfatase enzyme inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 2762-2767.	3.0	27
29	Chimeric microtubule disruptors. <i>Chemical Communications</i> , 2010, 46, 2907.	4.1	26
30	Estrone Sulfate Transport and Steroid Sulfatase Activity in Colorectal Cancer: Implications for Hormone Replacement Therapy. <i>Frontiers in Pharmacology</i> , 2017, 8, 103.	3.5	25
31	Nicotinamide Nucleotide Transhydrogenase as a Novel Treatment Target in Adrenocortical Carcinoma. <i>Endocrinology</i> , 2018, 159, 2836-2849.	2.8	25
32	The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers. <i>British Journal of Cancer</i> , 2007, 97, 1673-1682.	6.4	22
33	STX140, but Not Paclitaxel, Inhibits Mammary Tumour Initiation and Progression in C3(1)/SV40 T/t-Antigen Transgenic Mice. <i>PLoS ONE</i> , 2013, 8, e80305.	2.5	20
34	Endothelial cells play an essential role in the thermal hyperalgesia induced by nerve growth factor. <i>FASEB Journal</i> , 2003, 17, 1703-1705.	0.5	18
35	11-Oxygenated Estrogens Are a Novel Class of Human Estrogens but Do not Contribute to the Circulating Estrogen Pool. <i>Endocrinology</i> , 2021, 162, .	2.8	18
36	STX2171, a 17 β -hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model. <i>Endocrine-Related Cancer</i> , 2013, 20, 53-64.	3.1	17

#	ARTICLE	IF	CITATIONS
37	BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure. <i>British Journal of Cancer</i> , 2009, 100, 476-486.	6.4	16
38	Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17 β -hydroxysteroid dehydrogenase Type 3. <i>Molecular and Cellular Endocrinology</i> , 2009, 301, 251-258.	3.2	16
39	In touch with your feminine side: how oestrogen metabolism impacts prostate cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, R249-R266.	3.1	16
40	A new series of aryl sulfamate derivatives: Design, synthesis, and biological evaluation. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115406.	3.0	16
41	Cellular pathology changes in rat skin following intradermal injection of nerve growth factor: neutrophil-dependent and -independent events. <i>Journal of Pathology</i> , 2002, 197, 245-255.	4.5	12
42	In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer. <i>British Journal of Cancer</i> , 2014, 111, 300-308.	6.4	12
43	Synthesis and in vitro evaluation of piperazinyl-ureido sulfamates as steroid sulfatase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2019, 182, 111614.	5.5	11
44	Steroid sulfatase inhibiting lanostane triterpenes – Structure activity relationship and in silico insights. <i>Bioorganic Chemistry</i> , 2020, 95, 103495.	4.1	11
45	A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer. <i>Anticancer Research</i> , 2008, 28, 577-81.	1.1	10
46	SULFATION PATHWAYS: A role for steroid sulphatase in intracrine regulation of endometrial decidualisation. <i>Journal of Molecular Endocrinology</i> , 2018, 61, M57-M65.	2.5	8
47	The In Vitro and In Vivo Activity of the Microtubule Disruptor STX140 Is Mediated by Hif-1 Alpha and CAIX Expression. <i>Anticancer Research</i> , 2015, 35, 5249-61.	1.1	8
48	A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140. <i>Anticancer Research</i> , 2008, 28, 1483-91.	1.1	8
49	STX140 and STX641 cause apoptosis via the intrinsic mitochondrial pathway and down-regulate survivin and XIAP expression in ovarian and prostate cancer cells. <i>Anticancer Research</i> , 2009, 29, 3751-7.	1.1	8
50	The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer. <i>British Journal of Cancer</i> , 2008, 99, 1433-1441.	6.4	6
51	Steroid Sulfation in Adrenal Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3385-3397.	3.6	4
52	4th generation nonsteroidal aromatase inhibitors: An iterative SAR-guided design, synthesis, and biological evaluation towards picomolar dual binding inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2022, 240, 114569.	5.5	4
53	Steroid sulfation research has come a long way. <i>Journal of Molecular Endocrinology</i> , 2018, 61, E5-E6.	2.5	3
54	Steroid Sulfatase. , 2011, , 3528-3530.		0

#	ARTICLE	IF	CITATIONS
55	Steroid Sulfatase. , 2015, , 1-4.		0
56	Steroid Sulfatase. , 2015, , 4358-4360.		0